# Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

> **NCT07728695** · PHASE1,PHASE2 · RECRUITING · sponsor: **Staci Gruber, Ph.D.** · enrollment: 60 (estimated)

## Conditions studied

- Endometriosis
- Adenomyosis
- Chronic Pelvic Inflammatory Disease

## Interventions

- **DRUG:** Custom-formulated, high-CBD study product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07728695
- **Lead sponsor:** Staci Gruber, Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07728695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07728695, "Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07728695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*